SecBot SecBot
PTAB-TRIAL ·Filed Nov 10, 2026

SPRB

SPRUCE BIOSCIENCES, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 10h ago PTABPTAB Decision · ptacts.uspto.gov
PTAB institution decision (instituted)
Actionable Insight • Neutral

Monitor the final written decision expected within ~12 months. A finding of unpatentability could remove patent protection for a key treatment method, while a full defense would preserve it. No immediate stock-moving event.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$46.67
T+0 close · Nov 10, 2026 · via day close
Latest settled
−1.00%
T+1 · $46.20
Vs SPY
−2.32%
α at T+1
Next horizon
T+5
in 7h
  1. T+0 · Nov 10 $46.67entry
  2. T+1 · 6d ago −1.00%α −2.32% · $46.20
  3. T+4 · todayOpen
  4. T+5 · in 7h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

Executive Summary

The PTAB instituted a post-grant review (PGR2026-00061) of Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors, finding Neurocrine Biosciences' petition showed a reasonable likelihood of prevailing on at least one challenged claim. The trial is interlocutory; no claims have been cancelled yet.

PTAB Trial Details

Proceeding
PGR2026-00061
Proceeding Type
PGR (post-grant review)
Decision
Trial instituted
Company Role
Patent owner
Outcome for Patent Owner
Pending (trial to come)
Patent
U.S. 12,576,084
Patent Covers
METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
Challenged Claims
not stated
Next Step
Final written decision expected within approximately 12 months; the patent remains in force during trial

Key Facts

  • PTAB granted institution of PGR2026-00061 on November 10, 2026
  • Patent U.S. 12,576,084 covers methods for treating testicular and ovarian adrenal rest tumors
  • Petitioner is Neurocrine Biosciences, Inc.; patent owner is Spruce Biosciences, Inc.
  • Institution is interlocutory, no claims have been cancelled
  • Spruce's market cap is $134M with a normal daily move of 4.8%

Financial Impact

Patent protects a treatment method for adrenal rest tumors; loss could affect Spruce's product pipeline value, but no revenue or damages are stated in the decision

pipeline valueintellectual property

Risk Factors

  • Institution is interlocutory; the patent remains in force during trial
  • Final written decision could cancel some or all challenged claims, reducing patent protection
  • No financial figures or product revenue tied to the patent are stated in the decision

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 PTAB decision.

DocumentAccession Number
PTAB-TRIAL Data (Synthetic)ptab-PGR2026-00061-ins-SPRB

US Market Status

Market Closed · Opens Wed (9h 43m)

Subscribe to SecBot

Get Real-Time PTAB Decision Intelligence

Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ PTAB Decision · ptacts.uspto.gov Report published Nov 10, 2026